Design and Chemical Synthesis of Integrin Ligands

Methods in Enzymology

Volumn 426, Issue , 2007, Pages 463-503

  Heckmann, Dominik ^a   Kessler, Horst ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAIIBBETA3 INTEGRIN; ANGIOGENESIS INHIBITOR; ARGINYLGLYCYLASPARTIC ACID; CARBOXYL GROUP; CILENGITIDE; INTEGRIN; LIGAND; TIROFIBAN; TRIPEPTIDE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; ARGINYL-GLYCYL-ASPARTIC ACID; CYCLOPEPTIDE; OLIGOPEPTIDE;

AMINO ACID SEQUENCE; BINDING SITE; BIOCOMPATIBILITY; CHEMICAL STRUCTURE; CRYSTAL STRUCTURE; DRUG DESIGN; HYDROGEN BOND; IC 50; METASTASIS; MOLECULAR DOCKING; MOLECULAR INTERACTION; MOLECULAR MODEL; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN CONFORMATION; REVIEW; X RAY DIFFRACTION; ANIMAL; CHEMICAL MODEL; CHEMISTRY; HUMAN; PROTEIN SECONDARY STRUCTURE; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; HUMANS; INTEGRINS; LIGANDS; MODELS, CHEMICAL; MOLECULAR STRUCTURE; OLIGOPEPTIDES; PEPTIDES, CYCLIC; PROTEIN STRUCTURE, SECONDARY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 35148840122     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0076-6879(07)26020-3     Document Type: Review

References (149)

1. Abrams M.J., Juweid M., Tenkate C.I., Schwartz D.A., Hauser M.M., Gaul F.E., Fuccello A.J., Rubin R.H., Strauss H.W., and Fischman A.J. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J. Nucl. Med. 31 (1990) 2022-2028
2. Agrez M., Chen A., Cone R.I., Pytela R., and Sheppard D. The alpha v beta 6 integrin promotes proliferation of colon carcinoma cells through a unique region of the beta 6 cytoplasmic domain. J. Cell Biol. 127 (1994) 547-556
3. Arndt T., Arndt U., Reuning U., and Kessler H. Integrins in angiogenesis: Implications for tumor therapy. In: Weber G.F. (Ed). "Cancer Therapy: Molecular Targets in Tumor-Host Interactions" (2005), Horizon Bioscience, Hethersett, Norwich, United Kingdom
4. Arnold M., Cavalcanti-Adam E.A., Glass R., Blümmel J., Eck W., Kantlehner M., Kessler H., and Spatz J.P. Activation of integrin function by nanopatterned adhesive interfaces. Chem. Phys. Chem. 5 (2004) 383-388
5. Auernheimer J., Dahmen C., Hersel U., Bausch A., and Kessler H. Photoswitched cell adhesion on surfaces with RGD peptides. J. Am. Chem. Soc. 127 (2005) 16107-16110
6. Auernheimer J., and Kessler H. Benzylprotected aromatic phosphonic acids for anchoring peptides on titanium. Bioorg. Med. Chem. Lett. 16 (2006) 271-273
7. Auernheimer J., Zukowski D., Dahmen C., Kantlehner M., Enderle A., Goodman S.L., and Kessler H. Titanium implant materials with improved riocompatibility through coating with phosphonate-anchored cyclic RGD peptides. Chem. Biol. Chem. 6 (2005) 2034-2040
8. Aumailley M., Gurrath M., Müller G., Calvete J., Timpl R., and Kessler H. Arg-Gly-Asp constrained within cyclic peptides: Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett. 291 (1991) 50-54
9. Bach II A.C., Eyermann C.J., Gross J.D., Bower M.J., Harlow R.L., Weber P.C., and DeGrado W.F. Structural studies of a family of high affinity ligands for GPIIb/IIIa. J. Am. Chem. Soc. 116 (1994) 3207-3219
10. Bader B.L., Rayburn H., Crowley D., and Hynes R.O. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell 95 (1998) 507-519
11. Barlos K., Gatos D., Kallitsis J., Papaphotiu G., Sotiriu P., Yao W.Q., and Schäfer W. Synthesis of protected peptide-fragments using substituted triphenylmethyl resins. Tetrahedron Lett. 30 (1989) 3943-3946
12. Barluenga J., Gonzalez J.M., Garciamartin M.A., Campos P.J., and Asensio G. Acid-mediated reaction of bis(pyridine)iodonium(i) tetrafluoroborate with aromatic-compounds-a selective and general iodination method. J. Org. Chem. 58 (1993) 2058-2060
13. Barrett J.A., Crocker A.C., Damphousse D.J., Heminway S.J., Liu S., Edwards D.S., Lazewatsky J.L., Kagan M., Mazaika T.J., and Carroll T.R. Biological evaluation of thrombus imaging agents utilizing water soluble phosphines and tricine as coligands when used to label a hydrazinonicotinamide-modified cyclic glycoprotein IIb/IIIa receptor antagonist with 99mTc. Bioconjug. Chem. 8 (1997) 155-160
14. Barrett J.A., Damphousse D.J., Heminway S.J., Liu S., Edwards D.S., Looby R.J., and Carroll T.R. Biological evaluation of 99mTc-labeled cyclic glycoprotein IIb/IIIa receptor antagonists in the canine arteriovenous shunt and deep vein thrombosis models: effects of chelators on biological properties of [99mTc]chelator-peptide conjugates. Bioconjug. Chem. 7 (1996) 203-208
15. Biron E., Chatterjee J., and Kessler H. Efficient synthesis of N-methyl amino acids compatible for Fmoc solid-phase synthesis. Biopolymers 80 (2005) 522-523
16. Biron E., and Kessler H. Convenient synthesis of N-methylamino acids compatible with Fmoc solid-phase peptide synthesis. J. Org. Chem. 70 (2005) 5183-5189
17. Brooks P.C., Montgomery A.M., Rosenfeld M., Reisfeld R.A., Hu T., Klier G., and Cheresh D.A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79 (1994) 1157-1164
18. Cardillo G., Gentilucci L., Tolomelli A., and Tomasini C. Stereoselective synthesis of (2R,3S)-N-benzoylphenylisoserine methyl ester. J. Org. Chem. 63 (1998) 2351-2353
19. Carpino L.A. 1-Hydroxy-7-azabenzotriazole-an efficient peptide coupling additive. J. Am. Chem. Soc. 115 (1993) 4397-4398
20. Carpino L.A., and Han G.Y. 9-Fluorenylmethoxycarbonyl amino-protecting group. J. Org. Chem. 37 (1972) 3404-3409
21. Carpino L.A., Sadat-Aalaee D., Chao A.G., and DeSelms R.H. [(9-Fluorenylmethyl)oxy]carbonyl (FMOC) amino acid fluorides. Convienient new peptide coupling reagents applicable to the FMOC/tert-butyl strategy for solution and solid-phase syntheses. J. Am. Chem. Soc. 112 (1990) 9651-9652
22. Castner D.G., and Ratner B.D. Biomedical surface science: Foundations of frontiers. Surface Sci. 500 (2002) 28-60
23. Chang C.D., Felix A.M., Jimenez M.H., and Meienhofer J. Solid-phase peptide-synthesis of somatostatin using mild base cleavage of N-alpha-9-fluorenylmethyloxycarbonylamino acids. Int. J. Pept. Prot. Res. 15 (1980) 485-494
24. Clark R.A., Ashcroft G.S., Spencer M.J., Larjava H., and Ferguson M.W. Re-epithelialization of normal human excisional wounds is associated with a switch from alpha v beta 5 to alpha v beta 6 integrins. Br. J. Dermatol. 135 (1996) 46-51
25. Clemetson K.J., and Clemetson J.M. Integrins and cardiovascular disease. Cell. Mol. Life Sci. 54 (1998) 502-513
26. Coleman P.J., Askew B.C., Hutchinson J.H., Whitman D.B., Perkins J.J., Hartman G.D., Rodan G.A., Leu C.T., Prueksaritanont T., Fernandez-Metzler C., Merkle K.M., Lynch R., et al. Non-peptide alpha(v)beta(3) antagonists. Part 4: Potent and orally bioavailable chain-shortened RGD mimetics. Bioorg. Med. Chem. Lett. 12 (2002) 2463-2465
27. Coleman P.J., Brashear K.M., Askew B.C., Hutchinson J.H., McVean C.A., Duongle T., Feuston B.P., Fernandez-Metzler C., Gentile M.A., Hartman G.D., Kimmel D.B., Leu C.T., et al. Nonpeptide alphavbeta3 antagonists. Part 11: Discovery and preclinical evaluation of potent alphavbeta3 antagonists for the prevention and treatment of osteoporosis. J. Med. Chem. 47 (2004) 4829-4837
28. Dahmen C., Auernheimer J., Meyer A., Enderle A., Goodman S.L., and Kessler H. Improving implant materials by coating with nonpeptidic, highly specific integrin ligands. Angew. Chem. Int. Ed. 43 (2004) 6649-6652
29. Danilov Y.N., and Juliano R.L. (Arg-Gly-Asp)n-albumin conjugates as a model substratum for integrin-mediated cell adhesion. Exp. Cell Res. 182 (1989) 186-196
30. de Jong M., Bakker W.H., Krenning E.P., Breeman W.A., van der Pluijm M.E., Bernard B.F., Visser T.J., Jermann E., Behe M., Powell P., and Macke H.R. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur. J. Nucl. Med. 24 (1997) 368-371
31. Dechantsreiter M.A., Planker E., Marthä B., Lohof E., Hölzemann G., Jonczyk A., Goodman S.L., and Kessler H. N-methylated cyclic peptides as highly active and selective avb3 integrin antagonists. J. Med. Chem. 42 (1999) 3033-3040
32. DeNardo S.J., Zhong G.R., Salako Q., Li M., DeNardo G.L., and Meares C.F. Pharmacokinetics of chimeric L6 conjugated to indium-111- and yttrium-90-DOTA-peptide in tumor-bearing mice. J. Nucl. Med. 36 (1995) 829-836
33. Duggan M.E., Duong L.T., Fisher J.E., Hamill T.G., Hoffman W.F., Huff J.R., Ihle N.C., Leu C.T., Nagy R.M., Perkins J.J., Rodan S.B., Wesolowski G., et al. Nonpeptide alpha(v)beta(3). antagonists. 1. Transformation of a potent, integrin-selective alpha(IIb)beta(3). antagonist into a potent alpha(v)beta(3) antagonist. J. Med. Chem. 43 (2000) 3736-3745
34. Dutta A.S., and Morley J.S. Polypeptides. Part XIII. Preparation of alpha-aza-amino-acid (carbazic acid) derivatives and intermediates for the preparation of alpha-aza-peptides. J. Chem. Soc. Perkin Trans. 1 (1975) 1712-1720
35. Eble J.A., and Kühn K. "Integrin-Ligand Interaction." (1997), Springer-Verlag, Heidelberg
36. Edwards D.S., Liu S., Barrett J.A., Harris A.R., Looby R.J., Ziegler M.C., Heminway S.J., and Carroll T.R. New and versatile ternary ligand system for technetium radiopharmaceuticals: water soluble phosphines and tricine as coligands in labeling a hydrazinonicotinamide-modified cyclic glycoprotein IIb/IIIa receptor antagonist with 99mTc. Bioconjug. Chem. 8 (1997) 146-154
37. Egbertson M.S., Chang C.T., Duggan M.E., Gould R.J., Halczenko W., Hartman G.D., Laswell W.L., Lynch Jr. J.J., Lynch R.J., Manno P.D., Naylor A.M., Prugh J.D., et al. Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp. J. Med. Chem. 37 (1994) 2537-2551
38. Eisenwiener K.P., Powell P., and Macke H.R. A convenient synthesis of novel bifunctional prochelators for coupling to bioactive peptides for radiometal labelling. Bioorg. Med. Chem. Lett. 10 (2000) 2133-2135
39. Felding-Habermann B., Mueller B.M., Romerdahl C.A., and Cheresh D.A. Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. J. Clin. Invest. 89 (1992) 2018-2022
40. Feuerstein G., Ruffolo Jr. R., and Samanen J. The integrin αIIbβ3 (GPIIb/IIIa). A target for novel anti-platelet drugs. Pharm. Rev. Commun. 8 (1996) 257-265
41. Feuston B.P., Culberson J.C., Duggan M.E., Hartman G.D., Leu C.T., and Rodan S.B. Binding model for nonpeptide antagonists of α(v)β(3) integrin. J. Med. Chem. 45 (2002) 5640-5648
42. Fichna J., and Janecka A. Synthesis of target-specific radiolabeled peptides for diagnostic imaging. Bioconjug. Chem. 14 (2003) 3-17
43. Fields G.B., and Noble R.L. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J. Pept. Protein Res. 35 (1990) 161-214
44. Fischman A.J., Babich J.W., and Strauss H.W. A ticket to ride: Peptide radiopharmaceuticals. J. Nucl. Med. 34 (1993) 2253-2263
45. Freidinger R.M., Hinkle J.S., Perlow D.S., and Arison B.H. Synthesis of 9-fluorenylmethyloxycarbonyl-protected N-alkyl amino-acids by reduction of oxazolidinones. J. Org. Chem. 48 (1983) 77-81
46. Friedlander M., Brooks P.C., Shaffer R.W., Kincaid C.M., Varner J.A., and Cheresh D.A. Definition of two angiogenic pathways by distinct alpha v integrins. Science 270 (1995) 1500-1502
47. Friedlander M., Theesfeld C.L., Sugita M., Fruttiger M., Thomas M.A., Chang S., and Cheresh D.A. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc. Natl. Acad. Sci. USA 93 (1996) 9764-9769
48. Gante J. Peptidomimetics-tailored enzyme-inhibitors. Angew. Chem. Int. Ed. 33 (1994) 1699-1720
49. Gante J., Kessler H., and Gibson C. Synthesis of azapeptides. In: Goodmann A.F.M., Moroder L., and Toniolo C. (Eds). "Houben-Weyl: Methods of Organic Chemistry". Synthesis of Peptides and Peptidomimetics Vol. E22c (2003), Thieme Verlag, Stuttgart, New York
50. Gates V.L., Carey J.E., Siegel J.A., Kaminski M.S., and Wahl R.L. Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy. J. Nucl. Med. 39 (1998) 1230-1236
51. Geyer A., Mierke D.F., Unverzagt C., and Kessler H. Synthesis of cyclic thiohexapeptides. In: Schneider C.H., and Eberle A.N. (Eds). "Peptides 1992" (1993), ESCOM Science Publishers, Leiden, Netherlands
52. Geyer A., Müller G., and Kessler H. Conformational-analysis of a cyclic Rgd peptide-containing a Psi[CH2-NH] bond-a positional shift in backbone structure caused by a single dipeptide mimetic. J. Am. Chem. Soc. 116 (1994) 7735-7743
53. Gibson C., Goodman S.L., Hahn D., Hölzemann G., and Kessler H. Novel solid-phase synthesis of azapeptides and azapeptoides via Fmoc-strategy and its application in the synthesis of RGD-mimetics. J. Org. Chem. 64 (1999) 7388-7394
54. Gibson C., Sulyok G.A., Hahn D., Goodman S.L., Hölzemann G., and Kessler H. Nonpeptidic α(v)β(3) integrin antagonist libraries: On-bead screening and mass spectrometric identification without tagging. Angew. Chem. Int. Ed. 40 (2001) 165-169
55. Gibson C., Sulyok G.A.G., Hahn D., Goodman S.L., Hölzemann G., and Kessler H. Nonpeptidic αvβ3 integrin antagonist libaries: on-bead screening and mass spectometric identification without tagging. Angew. Chem. Int. Ed. 40 (2001) 165-169
56. Gilon C., Dechantsreiter M.A., Burkhart F., Friedler A., and Kessler H. Synthesis of N-methylated peptides. In: Goodmann A.F.M., Moroder L., and Toniolo C. (Eds). "Houben-Weyl: Methods of Organic Chemistry" Vol. E22c (2003), Thieme Verlag, Stuttgart, New York
57. Goligorsky M.S., Noiri E., Kessler H., and Romanov V. Therapeutic potential of RGD peptides in acute renal injury. Kidney Int. 51 (1997) 1487-1492
58. Gottschalk K.E., Gunther R., and Kessler H. A three-state mechanism of integrin activation and signal transduction for integrin alpha(v)beta(3). Chem. Biol. Chem. 3 (2002) 470-473
59. Gottschalk K.E., and Kessler H. A computational model of transmembrane integrin clustering. Structure 12 (2004) 1109-1116
60. Gray J.J. The interaction of proteins with solid surfaces. Curr. Opin. Struct. Biol. 14 (2004) 110-115
61. Gurrath M., Müller G., Kessler H., Aumailley M., and Timpl R. Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides. Eur. J. Biochem. 210 (1992) 911-921
62. Hammes H.P., Brownlee M., Jonczyk A., Sutter A., and Preissner K.T. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat. Med. 2 (1996) 529-533
63. Hartman G.D., Egbertson M.S., Halczenko W., Laswell W.L., Duggan M.E., Smith R.L., Naylor A.M., Manno P.D., Lynch R.J., Zhang G., Chang C.T.-C., and Gould R.J. Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. J. Med. Chem. 35 (1992) 4640-4642
64. Haubner R., Fissinger D., and Kessler H. Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the αvβ3 integrin for a new cancer therapy. Angew. Chem. Int. Ed. 36 (1997) 1374-1389
65. Haubner R., Gratias R., Diefenbach B., Goodman S.L., Jonczyk A., and Kessler H. Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin αvβ3 antagonists. J. Am. Chem. Soc. 118 (1996) 7461-7472
66. Haubner R., Schmitt W., Hölzemann G., Goodman S.L., Jonczyk A., and Kessler H. Cyclic RGD peptides containing beta-turn mimetics. J. Am. Chem. Soc. 118 (1996) 7881-7891
67. Haubner R., Sulyok G., Weber W., Linke W., Bodenstein C., Wester H.J., Kessler H., and Schwaiger M. Synthesis and first in vivo evaluation of [I-123]Aza-RGD-1: A radiolabled RGD-mimetic for the noninvasive determination of alpha(v)beta3 integrin expression. Eur. J. Nucl. Med. 28 (2001) 1175 1175
68. Haubner R., Weber W.A., Beer A.J., Vabuliene E., Reim D., Sarbia M., Becker K.F., Goebel M., Hein R., Wester H.J., Kessler H., and Schwaiger M. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]galacto-RGD. PLoS Med. 2 (2005) 244-252
69. Haubner R., and Wester H.J. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr. Pharm. Des. 10 (2004) 1439-1455
70. Haubner R., Wester H.J., Burkhart F., Senekowitsch-Schmidtke R., Weber W., Goodman S.L., Kessler H., and Schwaiger M. Glycosylated RGD-containing peptides: Tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J. Nucl. Med. 42 (2001) 326-336
71. Haubner R., Wester H.J., Reuning U., Senekowitsch-Schmidtke R., Diefenbach B., Kessler H., Stocklin G., and Schwaiger M. Radiolabeled alpha(v)beta3 integrin antagonists: A new class of tracers for tumor targeting. J. Nucl. Med. 40 (1999) 1061-1071
72. Haubner R., Wester H.J., Weber W.A., Mang C., Ziegler S.I., Goodman S.L., Senekowitsch-Schmidtke R., Kessler H., and Schwaiger M. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 61 (2001) 1781-1785
73. Hersel U., Dahmen C., and Kessler H. RGD modified polymers: Biomaterials for stimulated cell adhesion and beyond. Biomaterials 24 (2003) 4385-4415
74. Hirano Y., Okundo M., Hayashi T., Goto K., and Nakajima A. Cell-attachment activities of surface immobilized oligopeptides RGD, RGDS, RGDV, RGDT and YIGSR towards five cell lines. J. Biomater. Sci. Polym. Ed. 4 (1993) 235-243
75. Horton M.A., Taylor M.L., Arnett T.R., and Helfrich M.H. Arg-Gly-Asp (RGD). peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts. Exp. Cell Res. 195 (1991) 368-375
76. Huang X.Z., Wu J.F., Cass D., Erle D.J., Corry D., Young S.G., Farese Jr. R.V., and Sheppard D. Inactivation of the integrin beta 6 subunit gene reveals a role of epithelial integrins in regulating inflammation in the lung and skin. J. Cell Biol. 133 (1996) 921-928
77. Humphries M.J., McEwan P.A., Barton S.J., Buckley P.A., Bella J., and Mould A.P. Integrin structure: Heady advances in ligand binding, but activation still makes the knees wobble. Trends Biochem. Sci. 28 (2003) 313-320
78. Hynes R.O. A reevaluation of integrins as regulators of angiogenesis. Nat. Med. 8 (2002) 918-921
79. Isacke C.M., and Horton M.A. "The Adhesion Molecule Facts Book." (2000), Academic Press, London
80. Janssen M.L., Oyen W.J., Dijkgraaf I., Massuger L.F., Frielink C., Edwards D.S., Rajopadhye M., Boonstra H., Corstens F.H., and Boerman O.C. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res. 62 (2002) 6146-6151
81. Jeschke B., Meyer J., Jonczyk A., Kessler H., Adamietz P., Meenen N.M., Kantlehner M., Goepfert C., and Nies B. RGD-peptides for tissue engineering of articular cartilage. Biomaterials 23 (2002) 3455-3463
82. Jin H., and Varner J. Integrins: Roles in cancer developement and as treatment agents. Brit. J. Cancer 90 (2004) 561-565
83. Kantlehner M., Schaffner P., Finsinger D., Meyer J., Jonczyk A., Diefenbach B., Nies B., Hölzemann G., Goodman S.L., and Kessler H. Surface coating with cyclic RGD peptides stimulates osteoblast adhesion and proliferation as well as bone formation. Chem. Biol. Chem. 1 (2000) 107-114
84. Kessler H. Conformation and biological activity of cyclic peptides. Angew. Chem. Int. Ed. 21 (1982) 512-523
85. Kessler H., Diefenbach B., Finsinger D., Geyer A., Gurrath M., Goodman S.L., Hölzemann G., Haubner R., Jonczyk A., Müller G., vonRoedern E.G., and Wermuth J. Design of superactive and selective integrin receptor antagonists containing the RGD sequence. Lett. Pept. Sci. 2 (1995) 155-160
86. Kessler H., and Kutscher B. Synthesis of cyclic pentapeptide analogs of thymopoietin-cyclization with carbodiimide and 4-(dimethylamino)pyridine. Liebigs Ann. Chem. (1986) 869-892
87. Kim S., Bell K., Mousa S.A., and Varner J.A. Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am. J. Pathol. 156 (2000) 1345-1362
88. Knorr R., Trzeciak A., Bannwarth W., and Gillessen D. New coupling reagents in peptide chemistry. Tetrahedron Lett. 30 (1989) 1927-1930
89. Lacefield W.R. Materials characteristics of uncoated/ceramic-coated implant materials. Adv. Dent. Res. 13 (1999) 21-26
90. Li R., Babu C.R., Lear J.D., Wand A.J., Bennett J.S., and DeGrado W.F. Oligomerization of the integrin alphaIIbbeta3: Roles of the transmembrane and cytoplasmic domains. Proc. Natl. Acad. Sci. USA 98 (2001) 12462-12467
91. Li R., Mitra N., Gratkowski H., Vilaire G., Litvinov R., Nagasami C., Weisel J.W., Lear J.D., DeGrado W.F., and Bennett J.S. Activation of integrin alpha IIb beta 3 by modulation of transmembrane helix associations. Science 300 (2003) 795-798
92. Lohof E., Planker E., Mang C., Burkhart F., Dechantsreiter M.A., Haubner R., Wester H.J., Schwaiger M., Hölzemann G., Goodman S.L., and Kessler H. Carbohydrate derivatives for use in drug design: Cyclic alpha(v)-selective RGD peptides. Angew. Chem. Int. Ed. 39 (2000) 2761-2764
93. Mammen M., Choi S.K., and Whitesides G.M. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Ed. 37 (1998) 2755-2794
94. Manavalan P., and Momany F.A. Conformational energy studies on N-methylated analogs of thyrotropin releasing hormone, enkephalin, and luteinizing hormone-releasing hormone. Biopolymers 19 (1980) 1943-1973
95. Marinelli L., Gottschalk K.E., Meyer A., Novellino E., and Kessler H. Human integrin alphavbeta5: Homology modeling and ligand binding. J. Med. Chem. 47 (2004) 4166-4177
96. Marinelli L., Lavecchia A., Gottschalk K.E., Novellino E., and Kessler H. Docking studies on alphavbeta3 integrin ligands: pharmacophore refinement and implications for drug design. J. Med. Chem. 46 (2003) 4393-4404
97. Marinelli L., Meyer A., Heckmann D., Laveccia A., Novellino E., and Kessler H. Ligand binding analysis for human alpha5beta1 integrin: Strategies for designing new alpha5beta1 integrin antagonists. J. Med. Chem. 48 (2005) 4204-4207
98. Mazur R.H., James P.A., Tyner D.A., Hallinan E.A., Sanner J.H., and Schulze R. Bradykinin analogues containing N alpha-methyl amino acids. J. Med. Chem. 23 (1980) 758-763
99. McMurry T.J., Brechbiel M., Kumar K., and Gansow O.A. Convenient synthesis of bifunctional tetraaza macrocycles. Bioconjug. Chem. 3 (1992) 108-117
100. Merrifield R.B. Solid phase peptide synthesis. 1. Synthesis of a tetrapeptide. J. Am. Chem. Soc. 85 (1963) 2149-2154
101. Merrifield R.B. Solid-phase synthesis (Nobel Lecture). Angew. Chem. Int. Ed. 24 (1985) 799-810
102. Montgomery A.M., Reisfeld R.A., and Cheresh D.A. Integrin alpha v beta 3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc. Natl. Acad. Sci. USA 91 (1994) 8856-8860
103. Mould A.P., Symonds E.J., Buckley P.A., Grossmann J.G., McEwan P.A., Barton S.J., Askari J.A., Craig S.E., Bella J., and Humphries M.J. Structure of an integrin-ligand complex deduced from solution x-ray scattering and site-directed mutagenesis. J. Biol. Chem. 278 (2003) 39993-39999
104. Mousa S.A. Integrins as novel drug discovery targets: Potential therapeutic and diagnostic implications. Emerging Ther. Targets 44 (2000) 143-153
105. Müller G., Gurrath M., and Kessler H. Pharmacophore refinement of gpIIb/IIIa antagonists based on comparative studies of antiadhesive cyclic and acyclic RGD peptides. J. ComputerAided Mol. Des. 8 (1994) 709-730
106. Nip J., Rabbani S.A., Shibata H.R., and Brodt P. Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells. J. Clin. Invest. 95 (1995) 2096-2103
107. Otte A., Jermann E., Behe M., Götze M., Bucher H.C., Roser H.W., Heppeler A., Müller-Brand J., and Mäcke H.R. DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy. Eur. J. Nucl. Med. 24 (1997) 792-795
108. Pechy P., Rotzinger F.P., Nazeeruddin M.K., Kohle O., Zakeeruddin S.M., Humphrybaker R., and Gratzel M. Preparation of phosphonated polypyridyl ligands to anchor transition-metal complexes on oxide surfaces-application for the conversion of light to electricity with nanocrystalline Tio2 Films. J. Chem. Soc. Chem. Commun. 1 (1995) 65-66
109. Pfaff M., Tangemann K., Müller B., Gurrath M., Müller G., Kessler H., Timpl R., and Engel J. Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins. J. Biol. Chem. 269 (1994) 20233-20238
110. Pierschbacher M.D., Hayman E.G., and Ruoslahti E. Location of the cell-attachment site in fibronectin with monoclonal antibodies and proteolytic fragments of the molecule. Cell 26 (1981) 259-267
111. Pierschbacher M.D., and Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 309 (1984) 30-33
112. Pierschbacher M.D., and Ruoslahti E. Variants of the cell recognition site of fibronectin that retain attachment-promoting activity. Proc. Natl. Acad. Sci. USA 81 (1984) 5985-5988
113. Pierschbacher M.D., Ruoslahti E., Sundelin J., Lind P., and Peterson P.A. The cell attachment domain of fibronectin. Determination of the primary structure. J. Biol. Chem. 257 (1982) 9593-9597
114. Plow E.F., Haas T.A., Zhang L., Loftus J., and Smith J.W. Ligand binding to integrins. J. Biol. Chem. 275 (2000) 21785-21788
115. Poethko T., Thumshirn G., Hersel U., Rau F., Haubner R., Schwaiger M., Kessler H., and Wester H.J. Improved tumor uptake, tumor retention and tumor/background ratios of pegylated RGD-multimers. J. Nucl. Med. 44 Suppl. (2003) 46
116. Reynolds L.E., Wyder L., Lively J.C., Taverna D., Robinson S.D., Huang X., Sheppard D., Hynes R.O., and Hodivala-Dilke K.M. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat. Med. 8 (2002) 27-34
117. Roach P., Farrar D., and Perry C.C. Interpretation of protein adsorption: Surface-induced conformational changes. J. Am. Chem. Soc. 127 (2005) 8168-8173
118. Rojas A.J., and Ahmed A.R. Adhesion receptors in health and disease. Crit. Rev. Oral Biol. Med. 10 (1999) 337-358
119. Rose D.M., Pozzi A., and Zent R. Integrins as therapeutic targets. Emerging Ther. Targets 4 (2000) 397-411
120. Schmitt J.S. Lineare und zyklische Peptoide und Aza-Peptide als potentielle Tumortherapeutika und Isotopenmarkierung der humanen synovialen Phosphorlipase A2 (1998), Department of Organic Chemistry and Biochemistry, Technical University, Munich
121. Seftor R.E., Seftor E.A., Gehlsen K.R., Stetler-Stevenson W.G., Brown P.D., Ruoslahti E., and Hendrix M.J. Role of the alpha v beta 3 integrin in human melanoma cell invasion. Proc. Natl. Acad. Sci. USA 89 (1992) 1557-1561
122. Shemyakin M.M., Ovchinnikov Y.A., and Ivanov V.T. Topochemical investigations of peptide systems. Angew. Chem. Int. Ed. 8 (1969) 492-499
123. Smallheer J.M., Weigelt C.A., Woerner F.J., Wells J.S., Daneker W.F., Mousa S.A., Wexler R.R., and Jadhav P.K. Synthesis and biological evaluation of nonpeptide integrin antagonists containing spirocyclic scaffolds. Bioorg. Med. Chem. Lett. 14 (2004) 383-387
124. Smith J.W., Vestal D.J., Irwin S.V., Burke T.A., and Cheresh D.A. Purification and functional characterization of integrin alpha v beta 5. An adhesion receptor for vitronectin. J. Biol. Chem. 265 (1990) 11008-11013
125. Stragies R., Osterkamp F., Zischinsky G., Vossmeyer D., Kalkhof H., Reimer U., and Zahn G. Design and sysnthesis of a new class of selective integrin α5β1 antagonists. J. Med. Chem. (2007) (in press)
126. Sulyok G.A., Gibson C., Goodman S.L., Hölzemann G., Wiesner M., and Kessler H. Solid-phase synthesis of a nonpeptide RGD mimetic library: New selective alphavbeta3 integrin antagonists. J. Med. Chem. 44 (2001) 1938-1950
127. Sykaras N., Iacopino A.M., Marker V.A., Triplett R.G., and Woody R.D. Implant materials, designs, and surface topographies: Their effect on osseointegration. A literature review. Int. J. Oral Maxillofac. Implants 15 (2000) 675-690
128. Takagi J., Strokovich K., Springer T.A., and Walz T. Structure of integrin alpha5beta1 in complex with fibronectin. EMBO J. 22 (2003) 4607-4615
129. Tamkun J.W., DeSimone D.W., Fonda D., Patel R.S., Buck C., Horwitz A.F., and Hynes R.O. Structure of integrin, a glycoprotein involved in the transmembrane linkage between fibronectin and actin. Cell 46 (1986) 271-282
130. Taverna D., Moher H., Crowley D., Borsig L., Varki A., and Hynes R.O. Increased primary tumor growth in mice null for beta3- or beta3/beta5-integrins or selectins. Proc. Natl. Acad. Sci. USA 101 (2004) 763-768
131. Thakur M.L. Radiolabelled peptides: Now and the future. Nucl. Med. Commun. 16 (1995) 724-732
132. Thull R. Surface functionalization of materials to initiate auto-compatibilization in vivo. Materialwiss. Werkst. 32 (2001) 949-952
133. Thumshirn G., Hersel U., Goodman S.L., and Kessler H. Multimeric cyclic RGD peptides as potential tools for tumor targeting: Solid-phase peptide synthesis and chemoselective oxime ligation. Chemistry 9 (2003) 2717-2725
134. Tonelli A. The effects of isolated N-methylated residues on the conformational characteristics of polypeptides. Biopolymers 15 (1976) 1615-1622
135. Tranqui L., Andrieux A., Hudry-Clergeon G., Ryckewaert J.J., Soyez S., Chapel A., Ginsberg M.H., Plow E.F., and Marguerie G. Differential structural requirements for fibrinogen binding to platelets and to endothelial cells. J. Cell Biol. 108 (1989) 2519-2527
136. Turker R.K., Hall M.M., Yamamoto M., Sweet C.S., and Bumpus F.M. A new, long-lasting competitive inhibitor of angiotensin. Science 177 (1972) 1203-1205
137. Weber W.A., Avril N., and Schwaiger M. Relevance of positron emission tomography (PET) in oncology. Strahlenther. Onkol. 175 (1999) 356-373
138. Weide T., Modlinger A., and Kessler H. Spatial screening for the identification of integrin ligands. Top. Curr. Chem. 272 (2007) 1-50
139. Wermuth J. Alpha v beta 3 Inhibitoren durch räumliches Screening (1996), Department of Organic Chemistry and Biochemistry, Technical University, Munich
140. Wermuth J., Goodman S.L., Jonczyk A., and Kessler H. Stereoisomerism and biological activity of the selective and superactive alpha(v)beta(3) integrin inhibitor cyclo(-RGDfV-) and its retro-inverso peptide. J. Am. Chem. Soc. 119 (1997) 1328-1335
141. Wester H.J., Hamacher K., and Stocklin G. A comparative study of N.C.A. fluorine-18 labeling of proteins via acylation and photochemical conjugation. Nucl. Med. Biol. 23 (1996) 365-372
142. Wiseman G.A., Gordon L.I., Multani P.S., Witzig T.E., Spies S., Bartlett N.L., Schilder R.J., Murray J.L., Saleh M., Allen R.S., Grillo-Lopez A.J., and White C.A. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: A phase II multicenter trial. Blood 99 (2002) 4336-4342
143. Wiseman G.A., White C.A., Witzig T.E., Gordon L.I., Emmanouilides C., Raubitschek A., Janakiraman N., Gutheil J., Schilder R.J., Spies S., Silverman D.H., and Grillo-Lopez A.J. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. Clin. Cancer Res. 5 (1999) 3281-3286
144. Wu Y.L., Matsueda G.R., and Bernatowicz M. An efficient method for the preparation of omega,omega(')-bis-urethane protected arginine derivatives. Synth. Commun. 23 (1993) 3055-3060
145. Xiao T., Takagi J., Coller B.S., Wang J.S., and Springer T.A. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature 432 (2004) 59-67
146. Xiong J.P., Stehle T., Diefenbach B., Zhang R., Dunker R., Scott D., Joachimiak A., Goodman S.L., and Arnaout M.A. Crystal structure of the extracellular segment of integrin αvβ3. Science 294 (2001) 339-345
147. Xiong J.P., Stehle T., Zhang R., Joachimiak A., Frech M., Goodman S.L., and Arnaout M.A. Crystal structure of the extracellular segment of integrin avb3 in complex with an Arg-Gly-Asp ligand. Science 296 (2002) 151-155
148. Yang C. The effect of calcium phosphate implant coating on osteoconduction. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 92 (2001) 606-609
149. Yusuf-Makagiansar H., Anderson M.E., Yakovleva T.V., Murray J.S., and Siahaan T.J. Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune disease. Med. Res. Rev. 22 (2002) 146-167